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SHORT COMMUNICATION
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ABSTRACT
Starting from the analysis of the hypothetical binding mode of our previous furan-based hit (I), we suc-
cessfully achieved our objective to replace the nitro moiety, leading to the disclosure of a new lead exhib-
iting a strong activity against MbtI. Our best candidate 1h displayed a Ki of 8.8mM and its
antimycobacterial activity (MIC99¼ 250mM) is conceivably related to mycobactin biosynthesis inhibition.
These results support the hypothesis that 5-phenylfuran-2-carboxylic derivatives are a promising class of
MbtI inhibitors.
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Introduction
Tuberculosis (TB) is an infectious disease caused by an obligate
aerobic bacterium, known as Mycobacterium tuberculosis (Mtb).
When the bacilli are inhaled, they reach the alveolar spaces of the
lungs and are mainly ingested by macrophages. As a conse-
quence, TB primarily affects the lungs, but at later stages it can
also spread to other vital organs. Despite significant improve-
ments with respect to diagnosis, treatment, and preventive meas-
ures have been successfully implemented in many healthcare
systems around the world, this disease still remains the world’s
biggest threat to human health causing 54 million deaths
between 2000 and 20171. Standard therapeutic regimens have
remained substantially unchanged over the past 60 years with out-
dated drugs and very long therapies that are still used for the
treatment of new and relapse cases. In addition to the length of
the cure, other hurdles related to the management of TB infec-
tions include interactions with drugs used in comorbid conditions,
especially HIV, and severe side effects. All these issues contribute
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to determine a poor patient compliance that, together with the
improper use of TB antibiotics, has led to the insurgence of multi-
drug-resistant (MDR) and extensively drug-resistant (XDR) bacterial
strains2–4. As confirmed by the latest WHO report, drug resistance is
becoming a real emergency; therefore, there is a growing interest
in the development of novel anti-TB compounds5–8. A few of them
reached clinical trials and two drugs, delamanid and bedaquiline,
have been recently approved; however, more information on their
effectiveness, safety, and tolerability are still required because
severe side effects have been reported9,10. In this scenario, the
research of many more TB drug candidates to sustain an effective
and productive drug pipeline is pivotal. Targeting Mtb iron uptake
systems is now a validated strategy for the development of antimy-
cobacterial compounds, because iron is essential for Mtb survival in
the host and its acquisition is strongly correlated with virulence11.
Among the four different iron acquisition pathways used by Mtb,
the most thoroughly characterised one is based on the production
of two types of siderophores: carboxymycobactins, which acquire
iron extracellularly and transport it into the cytoplasm of the bac-
teria, and mycobactins, which facilitate the transport of iron
through the cell wall into the cytoplasm. Notably, targeting this bio-
synthetic process is an attractive strategy, because its impairment
lowers the pathogen virulence and survival without causing toxicity
issues. Indeed, as this pathway is absent in humans, the risk of off-
target effects is minimal; moreover, being an unexplored biological
process for the development of drugs, there is no known resistance
mechanism. The first step of the biosynthesis of these siderophores
is catalysed by the Mg2þ-dependent enzyme salicylate synthase
(MbtI), a validated pharmacological target12–15, whose crystal struc-
ture has been recently solved16.
In this context, the aim of our project is the identification of
new MbtI inhibitors as potential antitubercular agents. Our previous
computational studies generated a pharmacophore model, that
allowed the identification of the interesting hit compound I (Table
1). Then, a structure-activity relationship study on monosubstituted
derivatives underlined the importance of the nitro moiety for
potency14. However, the nitro group is considered a structural alert
for the development of a potential drug, since drugs containing
nitro groups have been extensively associated with mutagenicity
and genotoxicity17. On these bases, in the present work, we
designed additional analogs (compounds 1a-p, Table 1) exploring
other hitherto unconsidered pharmacophoric features and evaluat-
ing the possibility of replacing the nitro group.
Materials and methods
Chemistry
Compounds 1a,b,d–i,l–n,p were synthesised by a Suzuki-Miyaura
reaction18, followed by a base-catalysed hydrolysis of the ester
function19. Compounds 1c,j,k,o were synthesised by a Sandmayer
reaction20, starting from 2-furan carboxylic acid methyl ester and
the diazonium salts of the appropriate amines; the ester function
was then hydrolysed in basic conditions21. The general proce-
dures, the synthetic pathways (Supplementary Schemes 1 and 2),
the details concerning the specific synthetic steps and the analyt-
ical data are provided in the Supplementary Material.
MbtI enzymatic assays
Recombinant M. tuberculosis MbtI was produced and purified as
previously reported14. Enzyme activity was determined measuring
the production of salicylic acid by a fluorimetric assay slightly
modified from Vasan et al.12 Briefly, assays were performed at
37 C in a final volume of 400 mL of 50mM Hepes pH 7.5, 5mM
MgCl2, using 1–2 mM MbtI and the reactions were started by the
addition of chorismic acid and monitored using a Perkin-Elmer
LS3 fluorimeter (Ex. k¼ 305 nm, Em. k¼ 420 nm). Inhibition assays
were performed in the presence of the compound at 100 mM
(stock solution 20mM in DMSO), at 50 mM chorismic acid. For sig-
nificantly active compounds, IC50 and Ki values were determined.
To verify that the compounds were not PAINs, their ability to
inhibit MbtI activity was tested in the presence of 0.1mg/mL of
bovine serum albumin (BSA) or in the presence of 0.01% (v/v)
Triton X-100 to confirm that they did not act as aggregate, and in
the presence of 100mM of 1,4-dithio-DL-threitol (DTT) to exclude
an enzyme inhibition due to reaction with cysteines22.
Minimal inhibitory concentration determinations and
siderophore production assay
The MIC99 values of active compounds against M. bovis BCG were
determined in low-iron Chelated Sauton’s medium23, using the
resazurin reduction assay (REMA)24. Siderophore activity in the cul-
ture was tested in M. bovis BCG using the Universal CAS liquid
assay. To this purpose, M. bovis was grown in 7H9 medium, sub-
cultured in chelated Sauton’s medium and then diluted to an
Table 1. In vitro activity of compounds 1a–p.
R1
O
OH
O
R2
1a–i
R15CF3
1j–p
R15NO2
Code R2 Residual activity at 100 mM (%) MbtI IC50 (mM) Code R2
Residual activity
at 100 mM (%) MbtI IC50 (mM)
1a Cl 6.1 ± 2.5 28.5 ± 2.6 I** Cl 11.3 ± 4.2 17.9 ± 3.2
1b F 6.1 ± 1.1 27.6 ± 7.3 1j F 32.1 ± 2.4 –
1c Br 38.0 ± 3.7 – 1k Br 26.4 ± 4.8 –
1d OH 16.8 ± 2.7 35.9 ± 10.3 1l OH 13.9 ± 4.0 29.8 ± 4.2
1e CH3 19.3 ± 2.2 31.5 ± 9.6 1m CH3 13.2 ± 5.8 28.5 ± 1.5
1f NH2 13.1 ± 2.4 34.6 ± 10.9 1n NH2 13.5 ± 3.8 24.2 ± 5.4
1g CN 5.7 ± 1.5 18.5 ± 3.2 1o CN 5.0 ± 1.9 24.4 ± 5.9
1h CF3 3.9 ± 1.7 13.1 ± 2.0 1p CF3 25.1 ± 3.7 41.8 ± 5.3
1i m-CF3 64.3 ± 4.5 – – – – –
Only for compounds with residual activity 25%; new fluorimetric assay value determined for the sake
of comparison.
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OD600 of 0.01 in chelated Sauton’s containing different concentra-
tions of the test compound. After 15 days of incubation at 37 C,
cells were harvested, supernatants were used to perform CAS
assay and cell pellets were used for the determination of myco-
bactins. For CAS assay, an aliquot of 100 mL of supernatant was
mixed with 100 mL of CAS assay liquid solution in a 96-well plate,
incubated for 10min at room temperature, and the absorbance
was measured at 630 nm. For mycobactin determination, cell pel-
lets were extracted in ethanol overnight, then 0.1M FeCl3 in etha-
nol was added until no color change was observed. The mixture
was incubated at room temperature for 1 h, then mycobactins
were extracted in chloroform, washed with water, evaporated and
the residue was dissolved in methanol. The concentration of
mycobactins was determined measuring the absorbance at
450 nm (1% solution of mycobactins gives an absorbance of 42.8).
Cell viability assay
MRC5 human fibroblast lung cells were maintained at 37 C in a
humidified atmosphere containing 5% CO2, according to the
supplier’s indications. Cells (104) were plated in 96-well culture
plates. The day after seeding, vehicle or compounds were added
at different concentrations to the medium. Compounds were
added to the cell culture at a concentration ranging from 200 to
0.01 mM. Cell viability was measured after 96 h according to the
supplier’s instructions (Promega, cat. n G7571) with a Tecan
M1000 PRO instrument. IC50 values were calculated from logistic
dose-response curves.
Docking studies
All the compounds were docked into the minimised average
structure of MbtI complexed with the lead compound I14. The
software Gold with the four fitness functions implemented (i.e.
GoldScore, ChemScore, Astex Statistical Potential, and ChemPLP)
and plants were employed in this study as previously
reported14,25, since they have been already used showing good
results in the previous virtual screening study on MbtI inhibitors
performed in our laboratory15. The docking site was defined as
the region comprising all residues that stayed within 10Å from
Figure 1. Biological characterisation of 1h. The global reciprocal plot of data from MbtI steady-state kinetics analysis towards chorismic acid, in the presence of differ-
ent concentrations of 1h (A), highlights the competitive behaviour of the inhibitor. IC50 plots of 1h in the presence of BSA (green squares), Triton X-100 (red triangles)
and DTT (yellow diamonds) (B) confirm that the compound is not a PAIN. The Universal CAS assay performed on culture media of M. bovis BCG cells grown in the
presence of 1h (C), together with the determination of the mycobactins in the above-mentioned cells (D), confirm that the antimycobacterial activity is related to iron
uptake inhibition. All data are mean± SD of three replicates.
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the reference compound I. By applying the five docking methods,
five different binding dispositions (best-scored docking pose)
resulted from the docking of each ligand into the protein binding
site. The RMSD of these docking poses against the remaining four
was evaluated by using the rms_analysis software of the Gold
suite. On this basis, for each ligand docked into the protein bind-
ing site, a 5 5 matrix was generated reporting the RMSD results.
By using an in-house programme, these results were clustered, so
that among the five results, all of the similar docking poses were
grouped together26. We selected an RMSD clustering threshold of
2.0 Å; therefore, the so-obtained clusters contained the group of
poses that were less than 2.0 Å away from all others poses
belonging to the same cluster. For each compound, the binding
mode belonging to the most populated cluster identified by the
consensus docking evaluation was taken into consideration and
subjected to MD simulations.
MD simulations
All simulations were performed using AMBER 1627. General amber
force field (GAFF) parameters were assigned to the ligands,
whereas partial charges were determined using the AM1-BCC
method as implemented in the Antechamber suite of AMBER16.
MD simulations were carried out employing the ff14SB force field
at 300 K. Magnesium ion was inserted considering its disposition
and interaction into the 2FN1 PDB code. Ligand-protein com-
plexes were placed in a rectangular parallelepiped water-box and
solvated with a 20 Å water cap by using the TIP3P explicit solvent
model. Sodium ions were added as counterions in order to neu-
tralise the system. Before MD simulations, two steps of minimisa-
tion were performed; in the first stage, a position constraint of
500 kcal/(molÅ2) was applied to keep the protein fixed thus mini-
mising only water molecules. In the second stage, the whole sys-
tem was energy minimised through 5000 steps of steepest
descent followed by conjugate gradient (CG), until a convergence
of 0.05 kcal/(mol· Å2) and imposing a harmonic potential of
10 kcal/(molÅ2) to the protein a carbon. Particle mesh Ewald
(PME) electrostatics and periodic boundary conditions were used
in the simulations. The time step of the simulations was 2 fs with
a cutoff of 10 Å for the non-bonded interactions, while the SHAKE
algorithm was applied to keep all bonds involving hydrogen
atoms fixed. Constant-volume periodic boundary MD simulation
was carried out for the first 0.5 ns, during which the temperature
of the system was raised from 0 to 300 K. Then 19.5 ns of con-
stant-pressure periodic boundary MD was performed at 300 K,
using the Langevin thermostat in order to maintain constant the
temperature of the system. A harmonic force constraint of 10 kcal/
(mol· Å2) was applied to the protein a carbons during the first
3.5 ns, whereas in the last 16.5 ns no restraints were applied to
the system. All the obtained MD trajectories were analyzed using
the Cpptraj programme implemented in AMBER 16.
Result and discussion
In order to further develop our library of furan-based candidates,
we examined the substitution pattern at the para and ortho posi-
tions of the phenyl ring. Herein, we disclose additional SAR data;
firstly, we synthesised a phenyl di-substituted analog of I, charac-
terised by the presence of the trifluoromethyl group (1a), because
we knew that the more druggable p-CF3 in place of the p-NO2
group was still able to inhibit MbtI14. Compound 1a displayed
encouraging inhibiting properties (residual enzyme activity at
100 mM, as % RA, of 6.1 ± 2.5, IC50¼ 28.5 ± 2.6mM). Therefore, we
took into account this compound as a new hit and we focussed
on the effects of a variety of electron donating/withdrawing or
hydrophilic groups in the ortho position of the phenyl ring, keep-
ing the CF3 group in para position (1b–i). Then, the effects of the
previously analysed substituents in ortho position were evaluated
in the second series of derivatives 1j–p, bearing the original p-
NO2 group (Table 1).
The activity of all compounds (1a–p) was tested against the
recombinant MbtI, prepared and assayed as previously reported14.
The substitution of the chlorine atom with the fluorine in 1b did
not affect the activity, while the introduction of the bromine atom
in 1c diminished the inhibitory effect of the compound (% RA
38.0 ± 3.7), due to the low capability of bromine to act as
Figure 2. Minimised average structure of 1 h within MbtI binding site.
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hydrogen bond acceptor together with its higher atomic radius
determining a negative steric constraint. The presence of the elec-
tron donating groups in 1d, 1e, and 1f did not lead to an
improvement of the biological effects. When an electron with-
drawing moiety was introduced in the ortho position, as in 1g,
we detected an increased activity. This outcome was confirmed by
the introduction of an o-CF3 moiety that led to the disclosure of
1h, having an IC50 value comparable to that of the most active
inhibitor (I), previously identified. Derivative 1i was then prepared
and tested to assess the importance of having the electron with-
drawing moiety in ortho position of the phenyl ring; interestingly,
moving the CF3 to the meta position significantly decreased the
inhibitory activity of the compound. A parallel trend of biological
results was obtained for the p-NO2 derivatives 1j–p. These com-
pounds were prepared and tested to compare the impact of the
CF3 and NO2 groups on the activity and to better understand their
role in the interaction with the target. The outcomes reflected the
similar biological behaviour observed for this series (1j–p) with
respect to the previous one (1a–i), confirming the ability of CF3 to
act as a bioisostere of the nitro moiety, according to the bioisos-
terism between fluorine and carbonyl functionality28. Of note, the
presence of two CF3 substituents in 1h synergically contributed
to enhance the activity, as shown by the comparison of the IC50
value of 1h and the respective derivative 1p belonging to the
para-nitro series (13.1 vs. 41.8mM).
For the most active compound, 1h, an accurate biological ana-
lysis was thus performed (Figure 1). Kinetic analysis allowed the
determination of the Ki value 8.8 ± 0.7 mM, allowing the classifica-
tion of this compound as competitive inhibitor of MbtI. Then, add-
itional tests were performed to verify that 1h was not a PAIN
compound. The addition of BSA and Triton X-100 did not influ-
ence its IC50, proving that the compound did not form aggregates
with the target. Similarly, the addition of DTT did not impact on
1h activity, showing that the ligand did not interact with the cyst-
eine residues of the protein. To evaluate the antimycobacterial
activity of 1h we used the nonpathogenic M. bovis BCG, whose
siderophores closely resemble Mtb mycobactins29,30. The minimal
inhibitory concentration (MIC99) value, determined in iron-limiting
conditions in chelated Sauton’s medium, was similar to that of hit
I (250 mM versus 500 mM). Moreover, to assess if the antitubercular
activity was indeed related to iron uptake inhibition, the effects of
the compound on siderophore production were evaluated by
means of the Universal CAS liquid assay30. Firstly, the level of sid-
erophore activity in the medium was measured and the colorimet-
ric assay revealed that the removal of iron was inversely related to
the concentration of the compound. Similarly, the quantification
of mycobactins isolated from the cell pellet evidenced that the
concentration of mycobactins decreased at higher 1h concentra-
tions. All these outcomes suggested that the inhibitory effect
towards Mtb growth was due to mycobactin biosynthesis inhib-
ition. Finally, compounds I, 1h and 1p were selected for evaluat-
ing their antiproliferative activity against human MRC-5 fibroblasts.
The biological results showed that the three compounds did not
affect the growth of these normal cells (MRC-5, IC50> 100mM),
thus indicating the potentially low level of toxicity of this class
of compounds.
With the aim of elucidating the binding mode of this class of
derivatives, molecular modelling studies were performed on the
most active compound of the series. Compound 1h was sub-
jected to a consensus docking protocol and the result was refined
through 20 ns of MD simulation with explicit water molecules (see
Supplementary Material for details). Figure 2 shows the minimised
average structure of 1h bound to the catalytic site of MbtI. The
two aromatic rings of the ligand lay on the hydrophobic wall con-
stituted by I207, P251, T361, and L404, thus forming lipophilic
interactions with these residues. On the other side of the binding
site, the ligand core moiety shows multiple interactions with K438:
a hydrogen bond formed by the furan oxygen and a cation-p
interaction established through the phenyl ring, which also forms
additional hydrophobic contacts with the side chain of the resi-
due. The carboxylic group of 1h coordinates the Mg2þ ion and
also forms H-bonds with the backbone nitrogen of G270 and the
side chain of K205 that contribute to anchor the ligand to the
MbtI binding site. According to the experimental results, the p-CF3
group of the ligand replaces the p-NO2 group of the parent com-
pound I by forming two H-bonds with the backbone nitrogen of
R405 and G419, while the o-CF3 substituent of 1h shows an add-
itional hydrogen bond with the side chain of H334. The same con-
sensus docking and MD protocols were then applied on
compounds 1a and 1q to gain a better interpretation of the
obtained SAR. In agreement with the experimental data, the bind-
ing mode predicted for 1a confirmed the importance of the o-CF3
substituent of 1h. In fact, the o-chlorine atom of 1a does not
show any hydrogen bond with H334. Moreover, although the lig-
and perfectly chelates the Mg2þ ion, the presence of the chlorine
atom determines a small shift in the binding orientation that ham-
pers the formation of H-bonds with G270 and K205 predicted for
1h (Figure S1). Nevertheless, the presence of an o-CF3 moiety was
found to be detrimental when associated with the p-NO2 group
originally present in I, as observed for compound 1p.
Interestingly, MD simulations suggested that 1p is not able to
form the H-bond and cation-p interactions with K438 (Figure S2).
In order to establish the H-bond network among its p-NO2 group,
the backbone nitrogen of R405 and the side chain of Y385, 1p
moves toward these residues and slightly rotates toward K438,
which thus moves away from the ligand to avoid steric clashes.
Due to its orientation within MbtI binding site, 1p cannot even
interact with H334 through the o-CF3 as predicted for 1h.
To conclude, starting from the analysis of the hypothetical
binding mode of our previous furan-based hit I, we successfully
performed the bioisosteric replacement of the nitro group. Our
preliminary hit optimisation study led to the disclosure of a new
compound (1h) exhibiting a strong activity against MbtI, compar-
able to the most potent competitive inhibitor reported so far14.
Our best candidate 1h, characterised by the presence of two CF3
substituents in the ortho and para positions of its phenyl ring, dis-
played an IC50 value of 13.1 ± 2.0 mM (Ki¼ 8.8 ± 0.7 mM) and the
antimycobacterial activity showed by this compound
(MIC99¼ 250 mM) is conceivably related to mycobactin biosynthesis
inhibition. Moreover, preliminary assays against noncancerous
human fibroblast lung cells did not reveal cytotoxicity issues.
These results support the hypothesis that 5-phenylfuran-2-carbox-
ylic derivatives are a promising class of MbtI inhibitors and
allowed us to gather new information for a further optimisation of
this class of compounds.
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